POINT Biopharma Global Investor Relations Material

POINT Biopharma Global Inc. is a radiopharmaceutical company focused on developing and commercializing radioligands for cancer treatment. The company aims to enhance precision oncology through a portfolio of targeted radioligand therapies, leveraging its in-house manufacturing capabilities and secured supplies of key medical isotopes. POINT Biopharma actively participates in clinical trials, such as the SPLASH trial for metastatic castration-resistant prostate cancer. The company is headquartered in Indianapolis, Indiana, and its shares are listed on the NASDAQ.